TUO0 Stock Overview
Engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Terumo Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥16.60 |
| 52 Week High | JP¥18.10 |
| 52 Week Low | JP¥12.10 |
| Beta | 0.48 |
| 11 Month Change | 0% |
| 3 Month Change | -2.92% |
| 1 Year Change | 13.70% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| TUO0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 0.2% |
| 1Y | 13.7% | -6.8% | 8.5% |
Return vs Industry: TUO0 exceeded the German Medical Equipment industry which returned -1.1% over the past year.
Return vs Market: TUO0 exceeded the German Market which returned 2% over the past year.
Price Volatility
| TUO0 volatility | |
|---|---|
| TUO0 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: TUO0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TUO0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1921 | 30,207 | Hikaru Samejima | www.terumo.com |
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts.
Terumo Corporation Fundamentals Summary
| TUO0 fundamental statistics | |
|---|---|
| Market cap | €22.86b |
| Earnings (TTM) | €617.28m |
| Revenue (TTM) | €5.35b |
37.0x
P/E Ratio4.3x
P/S RatioIs TUO0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TUO0 income statement (TTM) | |
|---|---|
| Revenue | JP¥921.86b |
| Cost of Revenue | JP¥440.83b |
| Gross Profit | JP¥481.04b |
| Other Expenses | JP¥374.66b |
| Earnings | JP¥106.37b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 71.64 |
| Gross Margin | 52.18% |
| Net Profit Margin | 11.54% |
| Debt/Equity Ratio | 17.5% |
How did TUO0 perform over the long term?
See historical performance and comparison